Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Diffusion Pharmaceuticals Inc | DFFN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
4.40 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 4.14 - 7.785 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 4.40 | USD |
Diffusion Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
24.97M | 5.68M | - | 7.15M | -2.17M | -0.38 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Diffusion Pharmaceuticals News
Date | Time | Source | News Article |
---|---|---|---|
5/20/2024 | 15:07 | Edgar (US Regulatory) | Form 8-K - Current report |
5/15/2024 | 16:06 | Edgar (US Regulatory) | Form 8-K - Current report |
5/14/2024 | 15:06 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
5/10/2024 | 16:09 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under.. |
4/29/2024 | 15:06 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
4/23/2024 | 07:00 | Edgar (US Regulatory) | Form 8-K - Current report |
4/11/2024 | 18:55 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
4/05/2024 | 15:06 | Edgar (US Regulatory) | Form 8-K - Current report |
4/04/2024 | 06:00 | Edgar (US Regulatory) | Form 8-K - Current report |
3/29/2024 | 15:02 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
3/28/2024 | 07:36 | Edgar (US Regulatory) | Form 8-K - Current report |
3/18/2024 | 15:32 | Edgar (US Regulatory) | Form 8-K - Current report |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DFFN Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 6.21 | 7.785 | 4.14 | 5.73 | 15,949 | -1.81 | -29.15% |
3 Years | 1.035 | 14.025 | 0.249 | 0.937909 | 537,751 | 3.37 | 325.12% |
5 Years | 7.575 | 14.025 | 0.249 | 1.30 | 1,861,780 | -3.18 | -41.91% |
Diffusion Pharmaceuticals Description
Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. |